WHO Pharmaceuticals Newsletter No. 2, 2016

OMS, 19 de abril de 2016

Contenido

Asuntos Regulatorios

Carbamazepine .................................................................................. 5
Cisplatin ............................................................................................ 5
Entecavir hydrate .............................................................................. 5
Eribulin mesylate ............................................................................... 6
Esomeprazole magnesium hydrate .................................................... 6
Flunitrazepam .................................................................................... 6
Furosemide......................................................................................... 7
Fusafungine nose and mouth sprays .................................................. 7
Idelalisib ........................................................................................... .7
Imatinib mesylate .............................................................................. .8
Inhaled corticosteroids for chronic obstructive pulmonary disease ... 8
Loxoprofen ........................................................................................ .8
Methylphenidate hydrochloride ...........................................................9
Mirabegron ...........................................................................................9
Mycophenolate mofetil ........................................................................9
Opioid pain medicines ........................................................................ 10
Natalizumab .................................................................................... ..10
Piperacillin and tazobactam combination ............................................11
Piperacillin containing products (alone or in combination with tazobactam)  11
Risperidone and paliperidone ............................................................. 12
Simeprevir........................................................................................... 12
Sodium-glucose co-transporter-2 (SGLT2) inhibitors ....................... 12
Verteporfin ......................................................................................... 13

Seguridad de medicamentos
Bcr-Abl tyrosine kinase inhibitors........................................................ 14
Levonorgestrel-releasing intrauterine systems .................................. 14
Nicorandil ............................................................................................ 14
Pseudoephedrine containing over-the-counter products .................... 15
Rivaroxaban ......................................................................................... 15
Spironolactone and renin-angiotensin system drugs ........................... 15
Ticagrelor ............................................................................................ 16
Trametinib .............................................................................................16
Valproate ............................................................................................. 17
Vit.D3® (colecalciferol) ........................................................................17

Señales
Levetiracetam and impaired renal function .......................................... .18
Benznidazole and severe skin reactions ................................................24

Feature
Seasonal Malaria Chemoprevention and Pharmacovigilance,
Rabat, Morocco, February 2016 ..........................................................26


disponible en línea en http://bit.ly/1U8AZ2V